All In Biotech

Drug Trial Radar · NCT06412224

The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR)

An Exploratory ITT(Investigator Initiated Study) Study to Evaluate the Preliminary Safety and Efficacy of Single Subretinal Injection of RRG001 at the End of or After Vitrectomy in Subjects With PDR

Last checked: Nov 19, 2026Latest source record: May 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

Dec 20, 2023

Primary completion

Dec 31, 2024

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Li XiaorongAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shanghai Refreshgene Technology Co., Ltd.
First posted
May 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to slow down disease progression, reduce postoperative complications and decrease retreatment frequency in subjects with proliferative diabetic retinopathy (PDR) by administering a single subretinal injection of RRG001 gene therapy after vitrectomy.

Conditions

  • PDR - Proliferative Diabetic Retinopathy

Interventions

  • RRG001Drug

    Administered by subretinal injection. Dosage form: injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the incidence of DLTs (dose limiting toxicity analysis) at most 6 subjctsTime frame: Within 28 days after RRG001 administration
  2. To evaluate the incidence of AEs(Adverse Event) as assessed CTCAE 5.0 at most 6 subjctsTime frame: Within 24 weeks after RRG001 administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin medical university eye hospital

    Tianjin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.